Ethel S. Siris, MD, is the Madeline C. Stabile Professor of Clinical Medicine in the Department of Medicine, College of Physicians and Surgeons of Columbia University, and the Director of the Toni Stabile Osteoporosis Center of the Columbia University Medical Center, New York-Presbyterian Hospital, all in New York, New York. She is a graduate of Radcliffe College, Harvard University, and received her medical degree from the College of Physicians and Surgeons of Columbia University. An endocrinologist, she works as a clinician, as a clinical investigator and as a medical educator, all in the area of metabolic bone diseases, including osteoporosis and Paget's disease of bone. In her career she has participated in research activities with bisphosphonates, selective estrogen receptor modulators (SERMS) and RANKL inhibitors. Dr. Siris served as the Medical Director of NORA, the National Osteoporosis Risk Assessment, a public health initiative and longitudinal study of osteoporosis that included over 200,000 postmenopausal women in the US. Most recently her research activity has focused both on risk factors for osteoporosis and treatment adherence with osteoporosis medications.
Dr. Siris is the immediate past president of the National Osteoporosis Foundation and currently serves on the Board of Trustees of both the National Osteoporosis Foundation in the US and the International Osteoporosis Foundation. She is also a member and former vice chair of the Board of Directors of the Paget Foundation for Paget's Disease of Bone and Related Disorders. She has previously served on the Council of the American Society for Bone and Mineral Research and on the Endocrinologic and Metabolic Drugs Advisory Committee of the US Food and Drug Administration. She has published widely in the medical literature and is co-editor of the book, The Bone and Mineral Manual. Dr. Siris has been interviewed frequently on both television and radio and is often quoted in print media regarding osteoporosis.
Dr. Michael McClung is the founding director of the Oregon Osteoporosis Center. He graduated from Rice University in Houston and from the University of Texas Southwestern Medical School in Dallas. After his training in Internal Medicine at Parkland Hospital in Dallas, he completed a fellowship in Endocrinology at the National Institute of Health in Bethesda, Maryland. He then joined the faculty at the Oregon Health Sciences University, where he is an Associate Professor of Medicine. At OHSU, he founded a clinic devoted to the care of patients with disorders of bone and calcium metabolism that eventually grew into the Oregon Osteoporosis Center. In 1987, Dr. McClung joined the Department of Medical Education at Providence Medical Center where he is actively involved in the training of young physicians. He is board certified in both Internal Medicine and in Endocrinology and Metabolism, and is a fellow of the American College of Endocrinologists and the American College of Physicians.
Dr. McClung is an internationally recognized expert in the fields of osteoporosis and bone density testing. His Center has been involved in many of the important clinical studies that resulted in the availability of the medications now used to treat osteoporosis and Paget's disease of bone. He has published more than 200 papers and book chapters, is co-editor of a book for clinicians about disorders of bone and mineral metabolism and is a member of the editorial boards for several journals in his field.
Dr. McClung is widely known as an educator, translating clinical research information into practical strategies of evaluation and treatment for other physicians. He is an active member of multiple international societies focusing on bone diseases and their treatment. He serves as a member of the Council of Scientific Advisors for the International Osteoporosis Foundation, on the Scientific Advisory Board of the National Osteoporosis Foundation, and as a medical advisor for the Paget Foundation. He was a member of the World Health Organization Fracture Risk Task Force that led to the development of the FRAX® tool. He is a member of the global advisory boards for multiple companies and organizations. He has served on the Endocrinology and Metabolism Advisory Committee of the FDA and has participated in the development of evidence–based guidelines for the treatment of osteoporosis for several national and international societies.
